William Blair Issues Optimistic Forecast for SPRY Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – William Blair upped their Q4 2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a research note issued on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of $0.05 for the quarter, up from their previous forecast of $0.02. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.64) per share.

Other equities analysts have also recently issued research reports about the company. Raymond James upgraded ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $18.00 to $22.00 in a report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Finally, Leerink Partners lifted their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $24.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY opened at $14.01 on Friday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -27.47 and a beta of 0.90. The business has a 50-day moving average of $14.63 and a 200-day moving average of $11.73. ARS Pharmaceuticals has a fifty-two week low of $4.28 and a fifty-two week high of $18.51.

Insider Buying and Selling

In other ARS Pharmaceuticals news, major shareholder James E. Flynn sold 528,456 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the completion of the sale, the insider now directly owns 5,274,735 shares in the company, valued at $95,156,219.40. This trade represents a 9.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kathleen D. Scott sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $16.00, for a total transaction of $200,000.00. Following the sale, the chief financial officer now owns 13,199 shares of the company’s stock, valued at $211,184. This trade represents a 48.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,584,351 shares of company stock worth $24,152,378. Company insiders own 40.10% of the company’s stock.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of ARS Pharmaceuticals by 37.0% in the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after buying an additional 779,969 shares during the period. SG Americas Securities LLC boosted its stake in shares of ARS Pharmaceuticals by 861.5% in the second quarter. SG Americas Securities LLC now owns 111,592 shares of the company’s stock valued at $950,000 after buying an additional 99,986 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of ARS Pharmaceuticals in the third quarter valued at approximately $2,584,000. Bank of New York Mellon Corp lifted its stake in ARS Pharmaceuticals by 99.3% during the second quarter. Bank of New York Mellon Corp now owns 139,285 shares of the company’s stock worth $1,185,000 after purchasing an additional 69,394 shares during the last quarter. Finally, Raymond James & Associates bought a new stake in ARS Pharmaceuticals during the third quarter worth $2,969,000. 68.16% of the stock is currently owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.